JP7432532B2 - Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物 - Google Patents

Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物 Download PDF

Info

Publication number
JP7432532B2
JP7432532B2 JP2020572691A JP2020572691A JP7432532B2 JP 7432532 B2 JP7432532 B2 JP 7432532B2 JP 2020572691 A JP2020572691 A JP 2020572691A JP 2020572691 A JP2020572691 A JP 2020572691A JP 7432532 B2 JP7432532 B2 JP 7432532B2
Authority
JP
Japan
Prior art keywords
methyl
dihydro
oxo
naphthyridine
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020572691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529191A (ja
JPWO2020006018A5 (enExample
Inventor
アッペンダー・ベラパルチ
ルイス・エス・チュパック
チェタン・パドマカル・ダルネ
ミン・ディン
ロバート・ジー・ジェントルズ
ヤージョン・フアン
マンジュナタ・ナラヤナ・ラオ・カンブレ
スコット・ダブリュー・マーティン
ラジュ・マヌーリ
アイバー・エム・マクドナルド
リチャード・イー・オルソン
ハシブル・ラーマン
プラサダ・ラオ・ジャラガム
ソーミャ・ロイ
ゴピキシャン・トヌクヌル
シヴァスダル・ヴェライアー
ジャヤクマール・サンカラ・ウォリアー
シャオファン・ジェン
ジョン・エス・トカルスキー
ビレシュワル・ダスグプタ
コタ・ラトナカル・レディ
ティルベンカダム・ラジャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021529191A publication Critical patent/JP2021529191A/ja
Publication of JPWO2020006018A5 publication Critical patent/JPWO2020006018A5/ja
Application granted granted Critical
Publication of JP7432532B2 publication Critical patent/JP7432532B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
JP2020572691A 2018-06-27 2019-06-26 Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物 Active JP7432532B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862690439P 2018-06-27 2018-06-27
US62/690,439 2018-06-27
US201962840459P 2019-04-30 2019-04-30
US62/840,459 2019-04-30
PCT/US2019/039135 WO2020006018A1 (en) 2018-06-27 2019-06-26 Substituted naphthyridinone compounds useful as t cell activators

Publications (3)

Publication Number Publication Date
JP2021529191A JP2021529191A (ja) 2021-10-28
JPWO2020006018A5 JPWO2020006018A5 (enExample) 2022-07-04
JP7432532B2 true JP7432532B2 (ja) 2024-02-16

Family

ID=67439335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572691A Active JP7432532B2 (ja) 2018-06-27 2019-06-26 Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物

Country Status (27)

Country Link
US (3) US10669272B2 (enExample)
EP (1) EP3814348B9 (enExample)
JP (1) JP7432532B2 (enExample)
KR (1) KR102767739B1 (enExample)
CN (1) CN112654621B (enExample)
AU (1) AU2019291794B2 (enExample)
BR (1) BR112020026681A2 (enExample)
CA (1) CA3104654A1 (enExample)
CL (1) CL2020003260A1 (enExample)
DK (1) DK3814348T3 (enExample)
ES (1) ES2960754T3 (enExample)
FI (1) FI3814348T3 (enExample)
HR (1) HRP20231253T1 (enExample)
HU (1) HUE064531T2 (enExample)
IL (1) IL279728B2 (enExample)
LT (1) LT3814348T (enExample)
MX (1) MX2020013817A (enExample)
PE (1) PE20210469A1 (enExample)
PL (1) PL3814348T3 (enExample)
PT (1) PT3814348T (enExample)
RS (1) RS64641B1 (enExample)
SG (1) SG11202012972YA (enExample)
SI (1) SI3814348T1 (enExample)
SM (1) SMT202300466T1 (enExample)
TW (1) TW202019924A (enExample)
WO (1) WO2020006018A1 (enExample)
ZA (1) ZA202100555B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510108A (ja) * 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111471059B (zh) * 2019-01-23 2022-12-02 药捷安康(南京)科技股份有限公司 Pde9抑制剂及其用途
KR20220012244A (ko) 2019-04-29 2022-02-03 솔렌트 테라퓨틱스, 엘엘씨 Mrgx2의 억제제로서의 3-아미노-4h-벤조[e][1,2,4]티아디아진 1,1-디옥사이드 유도체
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
CN115210225A (zh) 2019-11-28 2022-10-18 拜耳公司 取代的氨基喹诺酮类作为免疫激活的dgkalpha抑制剂
CA3163107A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
GEP20247646B (en) 2019-11-28 2024-07-25 Bayer Ag Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CA3162985A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted quinazolinyl compounds useful as t cell activators
WO2021133752A1 (en) * 2019-12-23 2021-07-01 Bristol-Myers Squibb Company Substituted heteroaryl compounds useful as t cell activators
AR120823A1 (es) * 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
MX2022007130A (es) * 2019-12-23 2022-07-11 Bristol Myers Squibb Co Derivados de piperazina sustituidos utiles como activadores de celulas t.
ES2998500T3 (en) * 2019-12-23 2025-02-20 Bristol Myers Squibb Co Substituted quinolinonyl piperazine compounds useful as t cell activators
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CN120093741A (zh) * 2020-04-24 2025-06-06 拜耳公司 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑
WO2021258010A1 (en) * 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
KR102682398B1 (ko) * 2020-11-26 2024-07-05 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
CR20230415A (es) * 2020-11-30 2023-09-08 Kotobuki Pharmaceutical Co Ltd Compuesto de heteroarilcarboxamida
AU2021400725A1 (en) 2020-12-16 2023-08-03 Gossamer Bio Services, Inc. Compounds useful as t cell activators
WO2022187406A1 (en) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
EP4359411A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023122777A1 (en) * 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
EP4472963A1 (en) * 2022-02-01 2024-12-11 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
TW202342477A (zh) 2022-03-01 2023-11-01 香港商英矽智能科技知識產權有限公司 二醯基甘油激酶(DGK) α抑制劑及其用途
WO2023165525A1 (en) * 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
AR128668A1 (es) * 2022-03-01 2024-06-05 Insilico Medicine Ip Ltd INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS
WO2023178035A1 (en) 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023184327A1 (en) * 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
CN120813352A (zh) 2023-02-06 2025-10-17 拜耳公司 Dgk（二酰基甘油激酶）抑制剂的组合
CN116375654B (zh) * 2023-03-22 2024-12-31 湖北三峡实验室 一种由双甘肽制备2,5-二酮哌嗪的方法
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050266510A1 (en) 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
JP2009530384A (ja) 2006-03-21 2009-08-27 アヴァニール ファーマシューティカルズ 腫瘍壊死因子アルファ阻害（抑制）剤及びそれらのヒトの病気処理における使用
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324893A (en) 1979-04-18 1982-04-13 American Home Products Corporation 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
JP2005537247A (ja) 2002-06-27 2005-12-08 シエーリング アクチエンゲゼルシャフト 置換されたキノリンｃｃｒ５受容体アンタゴニスト
GB0230018D0 (en) 2002-12-23 2003-01-29 Syngenta Ltd Fungicides
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
WO2004087880A2 (en) 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
WO2005009967A2 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
BR122020016659B8 (pt) 2005-05-10 2021-07-27 Incyte Holdings Corp moduladores de 2,3-dioxigenase de indolamina e métodos de modulação de atividade de inibição e de imunossupressão
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
JP2007308402A (ja) 2006-05-17 2007-11-29 Sumitomo Chemical Co Ltd シンナモイル化合物及びその用途
JP2007308441A (ja) 2006-05-22 2007-11-29 Sumitomo Chemical Co Ltd 含複素環化合物及びその用途
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042489A2 (en) 2008-10-06 2010-04-15 Emory University Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
WO2010088414A2 (en) 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
SI2949670T1 (sl) 2009-12-10 2019-05-31 F. Hoffmann-La Roche Ag Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba
SG10201604336VA (en) 2010-03-04 2016-07-28 Macrogenics Inc Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
MX2012010014A (es) 2010-03-05 2012-09-21 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
ES2706412T3 (es) 2010-05-04 2019-03-28 Five Prime Therapeutics Inc Anticuerpos que se unen a CSF1R
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
CA2810359C (en) 2010-09-09 2021-06-22 Pfizer Inc. 4-1bb binding molecules
WO2012142498A2 (en) 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
NO2694640T3 (enExample) 2011-04-15 2018-03-17
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
US9006257B2 (en) 2012-02-09 2015-04-14 Glenmark Pharmaceuticals S.A. Bicyclic compounds as mPGES-1 inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
KR20150047593A (ko) 2012-08-31 2015-05-04 파이브 프라임 테라퓨틱스, 인크. 집락 자극 인자 1 수용체(csf1r)에 결합하는 항체로 질환을 치료하는 방법
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
EA201792214A1 (ru) 2015-04-10 2018-01-31 Араксис Фарма Ллк Соединения замещенного хиназолина
NZ742476A (en) 2015-12-17 2022-09-30 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
CN107216325B (zh) 2016-03-22 2019-06-25 上海医药工业研究院 萘啶酮类化合物、及其制备方法和应用
SI3558955T1 (sl) 2016-12-22 2021-12-31 Amgen Inc., Derivati benzizotiazola, izotiazola(3,4-b)piridina, kinazolina, ftalazina, pirido(2,3-d)piridazina in pirido(2,3-D)pirimidina, kot zaviralci KRAS G12C za zdravljenje pljučnega raka, raka trebušne slinavke ali kolorektalnega raka
WO2018134885A1 (ja) 2017-01-17 2018-07-26 初実 田中 支援奨励システムおよび支援奨励方法
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2019005883A1 (en) 2017-06-26 2019-01-03 University Of Virginia Patent Foundation COMPOSITIONS AND USES THEREOF
EP4509512A3 (en) 2018-03-07 2025-04-09 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
JP7312745B2 (ja) 2018-06-07 2023-07-21 第一三共株式会社 アゼチジン誘導体及びそのプロドラッグ
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
MX2020013895A (es) 2018-06-27 2021-07-21 Biogen Ma Inc Agentes inhibidores de ask1.
WO2020004594A1 (ja) 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
MX2020013805A (es) 2018-06-27 2021-03-09 Oscotec Inc Derivados de piridopirimidinona para uso como inhibidores de axl.
BR112020026580A2 (pt) 2018-06-27 2021-03-23 Proteostasis Therapeutics, Inc. (Fem) Compostos, composição farmacêutica e métodos para tratar um paciente

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503388A (ja) 2003-08-22 2007-02-22 アバニール・ファーマシューティカルズ マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用
US20050266510A1 (en) 2004-01-08 2005-12-01 Gajewski Thomas G T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
JP2009530384A (ja) 2006-03-21 2009-08-27 アヴァニール ファーマシューティカルズ 腫瘍壊死因子アルファ阻害（抑制）剤及びそれらのヒトの病気処理における使用
WO2017177037A1 (en) 2016-04-06 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023510108A (ja) * 2019-12-19 2023-03-13 ブリストル－マイヤーズ スクイブ カンパニー Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ

Also Published As

Publication number Publication date
EP3814348B9 (en) 2023-11-01
PE20210469A1 (es) 2021-03-08
PL3814348T3 (pl) 2023-09-11
IL279728B1 (en) 2023-03-01
TW202019924A (zh) 2020-06-01
ES2960754T3 (es) 2024-03-06
LT3814348T (lt) 2023-10-10
SI3814348T1 (sl) 2023-10-30
JP2021529191A (ja) 2021-10-28
HRP20231253T1 (hr) 2024-02-02
KR20210024586A (ko) 2021-03-05
US11713316B2 (en) 2023-08-01
AU2019291794B2 (en) 2022-06-16
ZA202100555B (en) 2022-07-27
MX2020013817A (es) 2021-03-09
BR112020026681A2 (pt) 2021-04-06
CN112654621A (zh) 2021-04-13
CN112654621B (zh) 2024-05-14
IL279728A (en) 2021-03-01
SG11202012972YA (en) 2021-01-28
AU2019291794A1 (en) 2021-02-11
DK3814348T3 (da) 2023-10-30
PT3814348T (pt) 2023-10-17
FI3814348T3 (fi) 2023-09-22
US10669272B2 (en) 2020-06-02
IL279728B2 (en) 2023-07-01
US20220324859A1 (en) 2022-10-13
KR102767739B1 (ko) 2025-02-12
US20200109140A1 (en) 2020-04-09
CA3104654A1 (en) 2020-01-02
EP3814348B1 (en) 2023-08-02
WO2020006018A1 (en) 2020-01-02
EP3814348A1 (en) 2021-05-05
US10954238B1 (en) 2021-03-23
CL2020003260A1 (es) 2021-04-23
SMT202300466T1 (it) 2024-01-10
HUE064531T2 (hu) 2024-04-28
RS64641B1 (sr) 2023-10-31

Similar Documents

Publication Publication Date Title
JP7432532B2 (ja) Ｔ細胞アクティベーターとして有用な置換ナフチリジノン化合物
JP7373512B2 (ja) Ｔ細胞アクティベーターとして有用なナフチリジノン化合物
JP7650864B2 (ja) Ｔ細胞アクティベーターとして有用な置換ピリドピリミジノニル化合物
JP7653440B2 (ja) Ｔ細胞アクティベーターとして有用な置換二環化合物
JP7712274B2 (ja) Ｔ細胞アクティベーターとして有用な置換ピペラジン誘導体
CN108431009A (zh) 作为RORγT抑制剂的取代的吲唑化合物及其用途
CN114667285A (zh) 抗病毒吡唑并吡啶酮化合物
US12145927B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2025059245A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compounds
EA043061B1 (ru) Замещенные нафтиридиноновые соединения, полезные в качестве активаторов т-клеток
HK40069881A (zh) 抗病毒吡唑并吡啶酮化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240205

R150 Certificate of patent or registration of utility model

Ref document number: 7432532

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150